Clinical Trial

Angiotensin-(1-7) Cardiovascular Effects in Aging

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-03-18; most recent amendment 2025-09-18.
Status change: Not Yet Recruiting → Recruiting 2022-10-21
Trial Details
NCT Number NCT05301192
Lead Sponsor Milton S. Hershey Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Aging
Enrollment 26 participants
Start Date 2022-12-09
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-19